Eric K. Singhi, MD
@lungoncdoc
Thoracic Medical Oncologist, Assistant Professor @MDAndersonNews | Patient education & young-onset lung cancer | 🫁#cancer #lcsm @LungCancerRx | Views my own
Ensuring patients with #cancer are well-informed about clinical trials is crucial! Proud to share our @JAMAOnc patient page, dedicated to ⬆️ inclusion & diversity in trial enrollment—#patienteducation is an important first step! 👥🔗 jamanetwork.com/journals/jamao… @OncoAlert #lcsm
@CharuAggarwalMD, @MNagasaka,@MattGubensMD,@LuisRaezMD , and @LeXiuning discuss considerations around managing systemic progression in EGFR-mutant lung cancer. Watch more here: hubs.li/Q03yWtgs0
Too many people are still diagnosed with #lungcancer far too late. We must find ways to detect this disease earlier — for everyone. Grateful for advocates like Leah & my friends at @YoungLungCancer leading the way. nytimes.com/2025/07/22/wel… #LCSM @nytimes
Timely poll given recent #FLAURA2 press release, as most agree that OS benefit matters most. IMHO, patient preference should have been ranked even higher.
‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! @OncoAlert
We'll be live within the next 15 minutes for our #BTGLung2025 livestream with @NarjustFlorezMD, @DrEdKim, and @lungoncdoc discussing the results of the community polling questions! See you soon! #lcsm #oncology
Polling Q9. IO in NSCLC‼️ What’s the most promising therapeutic approach to overcome immune checkpoint inhibitor resistance? #BTGLung2025 @OncLive @NarjustFlorezMD @DrEdKim
In this #YourStories episode, Dr. Eric Singhi (@LungOncDoc) discusses his mission to drown out #cancermisinformation with accurate, compelling knowledge, one post at a time. Listen now: brnw.ch/21wUnhi
Dr. @FawziAbuRous provides a “roadmap” for management after progression on immunotherapy. #BTGLung2025 @OncLive
Dr. @PatelOncology offers his thoughts on the 1L management of mNSCLC BOOKMARK this slide. #BTGLung2025 @OncLive @NarjustFlorezMD @DrEdKim
Polling Q8. AGA NSCLC‼️ Given the recent approval of Teliso-V, in your practice, are you routinely testing for c-MET overexpression? If so, when? #BTGLung2025 @OncLive @christinemphmd @NarjustFlorezMD @DrEdKim
Day two of #BTGLung2025 Dr. @christinemphmd discusses treatment advances in ROS1 and MET altered lung cancers. Key area with recent approvals and many questions regarding biomarker testing particularly for MET altered NSCLC #LCSM @NarjustFlorezMD @DrEdKim @OncLive
Dr. @christinemphmd nicely summarizes the evolving treatment landscape for patients with ROS1 positive NSCLC— incredible to see mPFS >45 months in this space! #BTGLung2025
Polling Q7. AGA NSCLC In BRAFV600E+ mNSCLC, should targeted therapy or IO be given first? #BTGLung2025 @NarjustFlorezMD @DrEdKim @OncLive @drgandara
Dr. Riess reminds us that it’s no longer just enough to say a “KRAS” mutation— nice figure here illustrating the spectrum of KRAS mutations and co-mutations in NSCLC. #BTGLung2025
Leave it to @BalazsHalmosMD to stay 1. current 2. informative and absolutely 3. hilarious 😂 Amazing conversations happening here at #BTGLung2025 discussing the perioperative early stage NSCLC treatment landscape! #ColdplayConcert @NarjustFlorezMD @DrEdKim
No better way to start the day than with a discussion about the management of early-stage NSCLC From what “Bulky” really means to what do after pCR And some laughs as @BalazsHalmosMD makes reference to Sisters Berenice Ruler in my catholic school @OncLive @lungoncdoc…
Polling Q6. Early stage NSCLC‼️ If a patient with early-stage NSCLC achieves a pCR after neoadjuvant chemoimmunotherapy, is adjuvant immunotherapy still necessary? #BTGLung25 @NarjustFlorezMD @DrEdKim @OncLive @DrRaviSalgia
A strong start to Day 2 of @OncLive Bridging The Gap 2025 with a high-impact session on early-stage NSCLC chaired by @DrRaviSalgia. Featuring talks and discussions from Jessica Donington, @TejasPatilMD, @ChristineBestv1, @BalazsHalmosMD, @HwakeleeMD, and @lungoncdoc.…
Polling Q5. Early Stage NSCLC‼️ After recent updates, is chemo-IO ready for routine clinical use to convert borderline resectable NSCLC into resectable disease? #BTGLung2025 @OncLive @NarjustFlorezMD @DrEdKim @BalazsHalmosMD @TejasPatilMD
Drs. @ElaineShumMD & @AnaVManana take on early stage #EGFR lung cancer updates & gaps! #BTGLung2025 #lcsm @OncLive